As of now, the FDA has set deadlines for compounders to stop producing tirzepatide products, but it is not enforcing the deadlines at the moment as the lawsuit is ongoing
Tirzepatide is the generic drug name for Mounjaro, which is the name brand and is FDA approved specific for chronic weight management, and helps to improve blood sugar (glucose) in adults with type 2 diabetes
Treatment must be provided by specialist weight management services, is limited to a maximum of 2 years, and requires specific weight loss targets to continue
For us physicians, it adds yet another prescribing pathway to navigate, while CMS, plans, and manufacturers keep negotiating around different prices that patients never really see
Tirzepatide was associated with a lower mortality rate at 12 months